News
High Standards
24. July 2019
EU 4 health
9. December 2020
Pharmaceutical Strategy
On Wednesday 25 November 2020, the European Commission has published its long awaited Communication setting out a new “Pharmaceutical Strategy for Europe”.
Europe’s Pharmaceutical Strategy has four main objectives:
- Ensuring access to affordable medicines for patients, and addressing unmet medical needs (e.g. in the areas of antimicrobial resistance, cancer, rare diseases);
- Supporting competitiveness, innovation and sustainability of the EU’s pharmaceutical industry and the development of high quality, safe, effective and greener medicines
- Enhancing crisis preparedness and response mechanisms, and addressing security of supply;
- Ensuring a strong EU voice in the world, by promoting a high level of quality, efficacy and safety standards.
The launch was preceded by a consultation round for stakeholders, where ESOP has given extensive input.
Since the pharmaceutical strategy also comprises adaptation of the pharmaceutical European legislative framework, the action of the upcoming years could potentially be very beneficial for all in the area of health-care, including oncology. We will continu to seek collaboration with the EU Sante and the MEPs involved in this work.
Ukraine
2. March 2020
Liaisons
 | Bogdan Larin, Kyiv LLC Yuria-Pharm Oncology Pharmacy Email: bl[at]esop.li |
 | Victoria Zapotochna, Kyiv Tory Group Ukraine LLC Website: Tory Group Email: vz[at]esop.li |
Current Information
News
27. February 2020
Protection of intellectual property
Question: How does the ESOP protect its members and their work results from intellectual exploitation?
Klaus: All colleagues know what has been waiting for them for 24 years. A small membership fee of 5 euros, but the opportunity to contribute both actively and with the support of the community to improving the care of cancer patients. From the very beginning, it was important to us that everyone could formally feel like a member with a small financial contribution and also actively and sustainably exchange ideas with colleagues in working groups. This has resulted in many projects, presentations and publications, and I would like to highlight the long-term studies on the effects of COVID, among other things.
We have never restricted the entire public, but have published all data on our website for everyone to access. Above all, this includes the continuous publication of the QuapoS in over 20 languages.
We have only made the 500-page commentary on the QuapoS available to members, so that everyone has access to their own personal working material. Now, as has been the case since 1996, we are working on the version of QuapoS 7, which can be approved by the delegates at the AGM on October 1 after a long period of committee work.
In connection with the fair treatment of the interested public with our results, however, we have to realize that some people who want to compete with us like to make extensive use of our work results.
Be it in lectures within the EUSOP specialization, in communication with our friendly societies or in other unfriendly actions, there is a misconception that they are trying to achieve supposed advantages for their own organization in the hope of gaining more support from the pharmaceutical industry.
Question: How do you yourself feel about negative behavior?
Klaus: I think that it is not okay to deprive our members of their work in order to gain financial benefits for your own purposes, and for this reason I believe that the people who represent our organization as officers must be clearly and unambiguously committed to the goals of the ESOP.
Reliability and clarity will be honored by all members. We disclose our objectives in publications and our finances in public statements, e.g. in the EU Transparency Register. We do not tolerate corruption or similar misconduct. It is good that the Committee for Fundamental Issues deals with this issue and presents the results to the delegates. I always assume that
ESOP Global: Response to the new EU pharmaceutical legislation proposal (2023)
About the past and present of ISOPP and ESOP Global (October 2023)
Question: Some colleagues have received an invitation for a virtual meeting of different nations with leadership. Where does the ISOPP get our email addresses from and what is this all about?
Klaus: Since we as ESOP operate our homepage openly for all interested parties, i.e. we allow everyone to participate in our activities free of charge, and all delegates can be contacted directly via the mailing list. The fact that the ISOPP is now showing interest in national issues in the context of oncological therapy only makes it clear that it has not missed the fact that we as ESOP Global have now brought together 70 countries and their active members for a fruitful exchange.
Question: Is this a new ISOPP strategy?
Klaus: We don’t know the decisions of the committees, but we can see the effects. When we founded the ESOP in 2000 because we thought it would be fruitful for better patient care to pass on knowledge to anyone who was interested, this was rejected by the countries, the majority of which belonged to the former Commonwealth. Since that days we propagate the goal worldwide: “Unity in diversity”
Question: Why is it that the ISOPP now wants to be open?
Klaus: There are certainly several reasons. Firstly, the ISOPP has started to organise its congresses annually rather than every two years, which puts it in strong competition with us. Especially in the years in which we organise the ECOP. The money that the industry, for example, budgets annually for advertising, including stands at congresses and satellite symposia, is limited. In this respect, the ISOPP is looking for national associations to participate in their congresses as co-organisers. On the other hand, the ISOPP also seems to have realised that the time of elitist associations is over if we not only want to support the development and use of new medicines, but also want to make knowledge available to all colleagues worldwide to support the entire treatment process. Through the EUSOP specialisation programme and the regional lectures it contains, we are not only strengthening our colleagues locally, but also our society. This also includes the ongoing and continuous development of quality standards. By already working on the 7th version, involving all experts worldwide, we are demonstrating our sustainability-orientated policy.
Question: You were the first elected president of the ISOPP in 1998. How do you feel about this unfriendly behaviour now?
Klaus: I don’t want to hide the fact that on the one hand this behaviour of long-time colleagues, such as the new ISOPP Vice President, who also participated as a delegate in the ESOP for the BOPA before BREXIT, hurts me. However, I have not given up hope of achieving fruitful cooperation in the future in the interests of patients. For this reason, on behalf of the ESOP Executive Committee, I have sent a detailed letter to the presidents of the ISOPP in which we offer a hand to reach an understanding on an equal footing, but at the same time make it a prerequisite to end the competition for finances and the organisation of the annual congress in the same year as the ECOP.
The lack of medicines is scaring people. What is the reason and how can it be countered in the long term? (December 2022)
What makes an organization strong that has dedicated itself to humanitarian goals and the activities of each individual take place unpaid in their free time? (November 2022)
One day with Oncology Pharmacy
Presented by 15 countries:
We present you the daily news from ECOP 5 (30th June to 2nd July)
>>Thursday<<
>>Friday<<
>>Saturday<<
Monthly Update Covid Situation Report (since August 2020)
26 October 2020
ESOP request to European Commission read more (öffnet in neuem Tab)”>-> read more
18 May 2020
Information letter concerning webinar every monday –> see the letter
11 May 2020
webiESOP – the fastest sharing of knowledge and experience
- Klaus Meier (ESOP P) Situation of our members and patients worldwide
- Christophe Bardin (ESOP VP) Epidemiology, Virology COVID19
Covid-19 Weekly Update Member Situation Report
6 April 2020
MPE publishes advice sheet
on coronavirus (Covid-19)
Mexico
19. January 2020
Delegates
 | Oscar Angel Morales Bustamante Email: oamb[at]esop.li |
| Jose Alberto Castillo Figueroa Email: jacf[at]esop.li |
  | Sandra Antonieta Palacios García Email: spg[at]esop.li |
Current Information
Ivory Coast
Liaison
 | Gaoussou Meite, Abidjan Email: mg[at]esop.li |
Current Information
Case Reports
7. January 2020
To create a new Case Report, please use the following templates:
Open / Download Actual Case Reports
| Titel | Download |
|---|---|
| Extravasation; Prevention and Treatment Approaches | Casereport 1/15 (clinical) |
| Elder Patients Enagement and Adherence Diagnosed With Metatstatic Renal Cell Carcinoma | Casereport 2013 (practise) |
| Multiple myeloma (plasmocytoma) with FUO and mucositis after autologous stem cell transplantation | Casereport 06 (clinical) |
| Pancytopenia and oesophageal thrush after irradiation and palliative chemotherapy of adenocarcinoma of the lung (NSCLC) | Casereport 05 (clinical) |
| Underststanding and Consulting Menopause & chemotherapy | Casereport 04/12 (practise) |
| Therapy and supportive care of a high-grade-non-Hodgkin’s lymphoma | Casereport 04 (clinical) |
| Adjuvant and palliative treatment of carcinoma of the sigmoid colon | Casereport 03 (clinical) |
| A 59 years old man with stage IV malign lung carcinoma | Casereport 04/11 (practise) |
| Adjuvant treatment of carcinoma of the sigmoid colon | Casereport 02 (clinical) |
| A 69 years old woman with stage IV small cell lung carcinoma | Casereport 12/10 (practise) |
| Non-small cell lung adenocarcinoma (NSCLC) with lung metastasis and lymphangitis carcinomatosis, stage IV | Casereport 01 (clinical) |
| 53 years old female patient with Stage IV Breast Carcinoma Lung Metastasis | Casereport 11/10 (practise) |
EJOP
20. December 2019
The European Journal of Oncology Pharmacy
The European Journal of Oncology Pharmacy is a peer-reviewed pharmaceutical journal in the field of cancer treatment. The journal encompasses all the recent issues related to the role of pharmacists in the prevention and treatment of cancers under its scope. This includes basic and applied researches on the synthesis or extraction, compounding, analysis, stability, pharmacology, side-effects, and clinical use of anticancer drugs and adjuvants therapies such as antiemetic, analgesic, or complementary medicines.
Now Open for Manuscript Submissions
European Journal of Oncology Pharmacy now seeks top-quality articles from the global research community which will aid in achieving high impact factor and largest diffusion. Authors are encouraged to share their ideas and valuable research outcomes through this Journal and provide the global readers updated and most important information in the mode of original articles, review articles, case reports, and short communications.
Benefits to Publishing in European Journal of Oncology Pharmacy!
- No submission fees
- Own the copyright to your work
- Clear ethical guidelines
- Compliant with open access funding mandates
More info at www.editorialmanager.com/EJOP
Yellow Hand
12. December 2019
Drugs with carcinogenic, mutagenic and/ or reproductive toxicity must must be handled with caution. Promoting Quality Standards for the Oncology Pharmacy Service ESOP offers a guideline for the transport of highly potent drugs and practical help.
Suppliers are asked to take precautions to avoid:
-breakage (e.g. plastic bottles instead of glass bottles)
-external contamination (e.g. cleaning, outer wrapping)
Thus, for the delivery of any cmr-drugs QuapoS guidelines insist on the following:
-secured, sealed, leak-proof cases
-a separate delivery
-clear labeling (in the spoken language of the recipient)
Labels should indicate:
-a warning of the highly potent drug
-that contact must be avoided
-that pregnant or breastfeeding women must not handle the product
-an emergency contact in case of spillage
News from Austria:
Standards für das Gebrauchsfertigmachen, die Applikation
und die Entsorgung von Zytostatika
Detailed Information
Labels Yellow Hand
